Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Inverness acquires Matritech to offer bladder cancer urine test

Inverness Medical Innovations : 21 April, 2008  (New Product)
Inverness Medical has acquired Matritech to offer the NMP22 BladderChek Test and NMP22 Test Kit for the rapid diagnosis and monitoring of early stage bladder cancer.
More commonly seen in men than women at a ratio of 3:1 (Ref 1), bladder cancer is linked to smoking and exposure to industrial chemicals, with approximately 356,600 new cases of bladder cancer reported worldwide each year1.

Simple to use, the rapid BladderChek Test can be performed outside of the laboratory with reliable results available during a single patient visit in just 30 minutes. Requiring only four drops of urine, the test is unaffected by the presence of blood in the sample which is commonly seen as one of the first symptoms of bladder cancer.

The painless and non-invasive Assay makes the NMP22 BladderChek Test and NMP22 Test Kit ideal for initial assessment as well as for monitoring before a cystoscopy is performed.

Both the rapid format and the ELISA test from Inverness Medical detect for elevated amounts of Nuclear Matrix protein (NMP22) in urine samples. Elevated amounts of NMP22 are present in the urine of most individuals with bladder cancer and are detectable even at early stages of the disease, making it an ideal marker for early diagnosis.

Bladder cancer has the highest rate of recurrence at 50 to 90 percent depending on the initial aggressiveness of the tumour. The NMP22 BladderChek Test and NMP22 Test Kit provide clinicians with the tools for an effective at risk-group screening and monitoring program in addition to cystoscopy procedures. This allows for rapid, accurate and cost effective detection of bladder cancer.

Ref 1 - IARC. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide (2002 estimates).
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo